- What ails Big PharmaA new book chronicles the uneasy relationship between money and drugs, and what it means for the rest of us.
- Ranbaxy’s empty promisesThe big manufacturer of generic drugs—including a non-branded version of Lipitor—has landed in trouble again, and once again it is promising to clean up its act. Should anybody believe the company?
- Painful prescriptionPharmacy benefit managers became a $250 billion industry by promising to save companies millions on employee medications. But critics say they make out better than their customers.
- Why the Supreme Court is wrong on generic drugsIts latest decision is based on a faulty premise.
- The latest to claim fraud at generic Lipitor maker Ranbaxy: Its ownersJapanese drugmaker Daiichi Sankyo has quietly stood by its decision to purchase Ranbaxy in 2008. Now, though, the company is publicly suggesting it was defrauded in the $4.6 billion acquisition.
- Dirty medicineThe epic inside story of long-term criminal fraud at Ranbaxy, the Indian drug company that makes generic Lipitor for millions of Americans.
- Maker of generic Lipitor pleads guilty to selling ‘adulterated drugs’Ranbaxy Laboratories pleads guilty to seven criminal counts.